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morphism was overrepresented in hypercalciuric stone 
formers. Urinary calcium excretion was not associated with 
CaSR polymorphism in the present sample. 
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 Introduction 
 Idiopathic hypercalciuria is one of the most common 
metabolic disturbances found in nephrolithiasis patients, 
occurring in up to 50% of cases but in less than 10% of 
the general population  [1–3] . Idiopathic hypercalciuria 
represents a systemic abnormality of calcium homeosta-
sis in which a dysregulation of calcium transport takes 
place in the kidneys, intestine and bones  [4, 5] . Patho-
physiological mechanisms may involve a primary renal 
calcium leak, primary intestinal calcium hyperabsorp-
tion, or an imbalance between bone resorption and for-
mation  [6] . Such disturbances can occur simultaneously, 
and secondary compensatory changes involve multiple 
hormones such as parathyroid hormone (PTH) and 1,25-
 dihydroxy-vitamin D 3 [1,25(OH) 2 D 3 ]  [7] .
 Serum 1,25(OH) 2 D 3 levels in patients with idiopathic 
hypercalciuria form a continuum from normal to high 
 [8] , so that elevated circulating 1,25(OH) 2 D 3 levels may 
account for the hypercalciuria in some but not all of these 
patients. Favus et al.  [8] observed that the number of pe-
ripheral blood monocytes of vitamin D receptors (VDRs) 
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 Abstract 
 Background/Aim: Some studies have identified an associa-
tion of kidney stone formation with vitamin D receptor (VDR) 
or calcium-sensing receptor (CaSR) polymorphisms. We 
aimed to evaluate the association between these polymor-
phisms with urinary calcium excretion (uCa) in calcium- 
stone-forming patients.  Methods: VDR polymorphism, de-
tected by  BsmI digestion, and 3 CaSR polymorphisms (G/T at 
codon 986, G/A at codon 990 and C/G at codon 1011), de-
tected by direct sequencing, were evaluated in 100 hyper-
calciuric (HCa) and 101 normocalciuric (NCa) calcium-stone-
forming patients.  Results:  The total allelic frequency of VDR 
polymorphism was: 16%  BB , 49%  Bb and 35%  bb . The preva-
lence of  bb genotype was significantly higher in the HCa 
when compared to the NCa group (43 vs. 27%). With respect 
to CaSR polymorphisms, 986S, 990G and 1011E variant alleles 
were detected, respectively, in 5, 4 and 3% of the whole sam-
ple and 5 CaSR haplotypes were identified: 94% ARQ (wild-
type), 3% SRQ, 1.5% AGQ, 1.0% ARE and 0.5% AGE. No statis-
tical differences have been observed between NCa and HCa 
with respect to these CaSR haplotypes.  Conclusions: The 
present study suggested that  bb homozygous for VDR poly-
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was twice as high in patients with idiopathic hypercalci-
uria compared to controls although the mean serum cal-
citriol levels were not. Therefore, a possible mechanism 
that could explain increased absorption of calcium in the 
gut, as well as bone mineral lability and abnormal renal 
tubule conservation of calcium would be altered tissue 
vitamin D response. Experimental studies have shown 
that the intestine, bones and kidneys of genetic hypercal-
ciuric stone-forming rats exhibited increased numbers of 
vitamin D receptors  [5, 9] and that prolongation of VDR 
half-life increases VDR tissue levels mediating increased 
VDR-regulated genes  [9] . Finally, a link between idio-
pathic calcium stone formation and the microsatellite 
marker D12S339 (near the VDR locus) has been estab-
lished in humans  [10] .
 Almost half of the patients with idiopathic hypercal-
ciuria have a positive family history of kidney stones  [7, 
11] and data from different geographic areas suggest a 
genetic background for hypercalciuria explaining at least 
50% of its variance  [11] . Nevertheless, idiopathic hyper-
calciuria is a complex trait that does not fit into classical 
Mendelian categories.
 Several studies about common allelic variations in 
VDR in disorders of calcium metabolism, using  Bsm I, 
 Apa I,  Taq I and  Fok I restriction enzymes have been per-
formed, but the results were controversial  [12–32] . While 
some studies disclosed an association between VDR 
polymorphism and bone mineral density (BMD)  [12–15] , 
others did not  [16–19] . Although the link between stone 
formation and VDR has not yet been clarified, and these 
polymorphisms do not alter the amino acid sequence of 
the VDR protein, allelic differences in the 3  untranslated 
region may alter the regulation of messenger RNA stabil-
ity and/or translation and thus affect vitamin D activity, 
or even mediate calcitriol action in the regulation of ex-
pression of other target genes involved in renal tubular 
calcium reabsorption  [12, 27, 33] . In addition, even if a 
specific VDR genotype does not provide evidence for a 
VDR defect per se, it could be a marker for the disease 
that could aid in the identification of a possible disease 
locus  [12] . Evaluation of VDR polymorphisms among 
kidney stone formers, hypercalciuric or not, have shown 
distinct findings  [16, 20–32] . Some investigators found a 
positive association between polymorphic variations in 
VDR gene with risk or recurrence of stone formation  [27–
29] but other studies were negative  [30, 31] . As for urinary 
calcium, a few studies reported higher calcium excretion 
related to specific genotypes  [21, 24, 32] while others did 
not  [20, 22, 25, 26] .
 The G-protein-coupled extracellular-calcium-sens-
ing receptor (CaSR) is a key regulator of PTH secretion 
and renal tubular calcium reabsorption in response to 
blood calcium levels  [34] . Activation of the renal CaSR 
may decrease renal tubule calcium reabsorption and 
cause hypercalciuria through suppression of calcium-
sensitive potassium channel activity. The CaSR gene is 
also regulated by VDR, and pathologically elevated VDR 
levels observed in genetic hypercalciuric stone-forming 
rats have been implicated in the increased renal CaSR 
mRNA induced by 1,25(OH) 2 D 3 , possibly contributing 
to hypercalciuria  [35] . Three single-nucleotide polymor-
phisms, causing nonconservative amino acid changes 
have been described on exon 7, encoding the intracellu-
lar domain of CaSR. The most common single-nucleo-
tide polymorphism is represented by a substitution of 
guanine/thymine at codon 986, leading to the Ala986Ser 
variant  [36, 37] and the other two, less frequent substitu-
tions, are  Arg990Gly and Gln1011Glu (substitutions of 
adenine/guanine at codon 990 and cytosine/guanine at 
codon 1011, respectively)  [37] . One of the pioneering 
studies performed by Cole et al.  [36] showed a positive 
association between serum calcium and A986S poly-
morphism in women. Subsequent association studies be-
tween different CaSR polymorphisms and urinary cal-
cium have been controversial, resulting in positive  [38–
42] or negative findings  [43, 44] . Nevertheless, only a few 
of these studies had been conducted in calcium-stone-
forming patients  [38, 42] . Association with BMD was de-
tected by some investigators  [45, 46] but not by others 
 [43, 47–49] .
 Therefore, the aim of the present study was to evaluate 
a potential association of VDR and CaSR gene polymor-
phisms with urinary calcium excretion in stone-forming 
patients.
 Subjects and Methods 
 Two-hundred and one adult calcium-stone-forming patients 
(103 males and 98 females) from the Renal Lithiasis Unit of the 
Nephrology Division of the Federal University of São Paulo were 
included in the present study. Stone disease had been diagnosed 
on the basis of renal colic with confirmed hematuria and voiding 
of a calculus and/or previous surgical or endoscopic removal of 
stone(s), and/or radiographic evidence of stone(s). Patients were 
classified as normocalciuric or hypercalciuric based on the results 
of 24-hour urine samples available from their medical records. 
Data concerning the presence of other metabolic abnormalities 
related to stone formation were also obtained from these records. 
As the report of stone analysis was not available in most of the 
records, only those patients with evidence of uni- or bilateral ra-
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dio-opaque stones, consistent with calcium composition, were se-
lected for this study. Exclusion criteria included: abnormal renal 
function, pregnant or postmenopausal women, men aged  6 65 
years, cystinuria, renal tubular acidosis, inflammatory bowel dis-
ease, primary hyperparathyroidism and other diseases affecting 
calcium metabolism (hyperthyroidism, acromegaly, sarcoidosis, 
diabetes or neoplasia), use of drugs such as corticosteroids, anti-
convulsants, estrogen or vitamin D. Written consent was ob-
tained from all patients and the study was approved by the Ethics 
Committee of the Federal University of São Paulo.
 All patients had been previously submitted to a metabolic 
evaluation including serum determinations of calcium, creati-
nine, uric acid and 24-hour urine collections (mean of 2 noncon-
secutive samples), under an unrestricted diet. Idiopathic hyper-
calciuria was defined by serum calcium within normal limits and 
24-hour urinary excretion of calcium  6 250 or 300 mg/24 h (for 
females and males, respectively). Hyperuricosuria was consid-
ered as urinary uric acid  1 750 or 800 mg/24 h (for females and 
males, respectively), hypocitraturia as urinary citrate  ! 320 mg/
24 h. Calcium was determined by atomic absorption spectropho-
tometry (Perkin Elmer Atomic Spectrophotometer 3110; Nor-
walk, Conn., USA), uric acid, by the uricase method (Hitachi 912; 
Roche, Mannheim, Germany) and citrate by an enzymatic assay 
using citrate lyase as described elsewhere  [50] . Creatinine was de-
termined according to a modified Jaffé reaction by isotope dilu-
tion mass spectrometry. Sodium was determined by an ion-selec-
tive electrode. BMD was assessed by dual-energy X-ray absorpti-
ometry at lumbar spine and femoral neck sites, using a DPX 
model apparatus (Lunar Radiation Corporation, Madison, Wisc., 
USA). Data concerning evaluation of BMD were available from 
146 medical records. Osteopenia was defined by a T-score value 
below –1.0 in the L 2 –L 4 lumbar spine and/or femur neck accord-
ing to WHO criteria  [51] .
 VDR and CaSR Genotyping 
 Blood samples were obtained for genotyping of both VDR and 
CaSR polymorphisms and genomic DNA was extracted from pe-
ripheral blood leukocytes using the Puregene DNA Isolation Kit 
(Gentra Systems, Minneapolis, Minn., USA).
 VDR gene polymorphism was identified for polymerase chain 
reaction (PCR) amplification of the  Bsm I  restriction site located 
between exon 7 and the 3  -UTR, using the following primers  [12] : 
5  -CAACCAAGACTACAAGTACCG-CGTCAGTGA-3  and 5  -
AACCAGCGGGAAGAGGTCAAGGG-3  . Briefly, PCR was car-
ried out in a 50-  l reaction volume containing 500 ng of DNA, 
0.4   M of each primer, 0.5 nmol dNTPs, 1.5 m M MgCl 2 and 2.5 U 
of  Taq  DNA polymerase (all reagents from Invitrogen). The PCR 
conditions were 94 ° C, 5 min, 94 ° C, 1 min, 61 ° C, 90 s, 72 ° C,
2 min, for 30 cycles and then 72 ° C for 10 min and 4 ° C, using an 
MJ Research thermal cycler. PCR products were submitted to di-
gestion with the  Bsm I endonuclease at 65 ° C for 3 h, and then 
separated electrophoretically on 2% agarose gel containing ethid-
ium bromide.  BsmI  alleles were defined by capitals in the absence 
of the restriction site  (B), and lowercase letters in the presence of 
the restriction site  (b). 
 Part of exon 7 of the CaSR gene comprising the 3 single-nucle-
otide polymorphisms (G/T at codon 986, A/G at codon 990, and 
C/G at codon 1011) were amplified by PCR as described elsewhere 
 [38] using primers 5  -CAGAAGGTCATCTTTGGCAGCGGCA-
3  and 5  -TGCAGACCTGTTTCCTGGACGGTC-3  , sequences 
that flank the polymorphic site giving an amplimer of 206 bp. 
Purified PCR products were submitted to direct sequencing using 
a ready reaction mix (ABI PRISM Big-Dye Terminator Cycle Se-
quencing Ready Reaction Kit; Applied Biosystems, Foster City, 
Calif., USA) and the same forward primer as for PCR. Sequence 
products were generated during 25 cycles of the following steps: 
15 s at 96 ° C, 10 s at 50 ° C, and 2 min at 60 ° C. Nonincorporated 
dye terminators were removed by ethanol/sodium acetate precip-
itation. Afterwards, dyed samples were denatured in 20   l of 
Template Suppression Reagent (Applied Biosystems) at 95 ° C for 
10 min and cooled on ice for 15 min. The ABI PRISM 310 Genet-
ic Analyzer (Applied Biosystems) was used for capillary electro-
phoresis.
 Statistical Analysis 
 Data are presented as means  8 standard deviation (SD). The 
Mann-Withney test was used to compare normocalciuric versus 
hypercalciuric patients. The Kruskal-Wallis analysis of variance 
test was performed to compare differences between the different 
genotypes or haplotypes of each polymorphism in the normocal-
ciuric or hypercalciuric groups of patients. The   2 or Fisher’s exact 
test was used to compare the frequencies of VDR genotypes and 
CaSR haplotypes in the normocalciuric and hypercalciuric 
groups. Relative risk to be hypercalciuric was estimated by calcu-
lation of the odds ratio (OR) and its 95% confidence interval (95% 
CI). Linkage disequilibrium between SNPs and allele and haplo-
type frequencies were calculated using Haploview 3.32 software. 
Statistical power calculations were conducted with Quanto ver-
sion 1.2.3 software using empirically observed allele frequencies 
and the hypercalciuric phenotype. For the studied polymorphism 
of the VDR gene, our sample had 80% power to disclose an OR of 
at least 2.2 associated with the  b allele. For the much rarer CaSR 
studied polymorphisms, our sample allowed 80% power to detect 
OR in the order of 3.0, 3.3 and 3.7, respectively, for the 986S, 990G, 
and 1011E variant alleles.
Table 1. Serum and urine biochemistry in all patients according 
to VDR genotypes (means 8 SD except for number)
BB Bb bb
Patients 32 (16%) 99 (49%) 70 (35%)
Gender, M/F 18/14 47/52 34/36
Age, years 43811 37810 41813
sCa, mg/dl 9.480.6 9.480.6 9.480.4
sCr, mg/dl 0.980.2 0.980.2 1.081.2
sUrAc, mg/dl 5.081.3 5.281.7 4.981.8
uCa, mg/24 h 2638107 2288102 2708102
uNa, mEq/24 h 219884 2278115 214871
uUrAc, mg/24 h 5888180 5738275 6238229
uCit, mg/24 h 4418257 3858254 3428218
Conversion factors for SI units are: serum calcium (sCa) 0.2495 
(for mmol/l), serum creatinine (sCr) 88.4 and serum uric acid 
(sUrAc) 59.48 (for mol/l); urinary calcium (uCa) 0.02495, uri-
nary sodium (uNa) 1.0 and urinary uric acid (uUrAc) 5.948 (for 
mmol/day); urinary citrate (uCit) 0.053 (for mmol/l).
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 Results 
 The allele frequencies of the VDR polymorphism in 
the whole sample of 201 calcium-stone-forming patients 
were 16, 49 and 35%, respectively for  BB ,  Bb and  bb , as 
shown in  table 1 . These genotype frequencies at polymor-
phic sites did not deviate from those expected according 
to the Hardy-Weinberg equilibrium. Analysis of patients 
grouped by these 3 genotypes showed no differences in 
mean age or gender distribution. In  bb patients, mean 
urinary excretion of calcium was higher than in  Bb pa-
tients (270  8 102 vs.  228  8 102 mg/24 h), but the differ-
ence did not reach statistical significance. The other 
mean serum and urine biochemical parameters were not 
statistically different between VDR genotypes.
 Patients were then classified as hypercalciuric (n = 
100, 52 M/48 F, 38  8 11 years old) or normocalciuric
(n = 101, 51 M/50 F, 39  8 11 years old). Hypercalciuric 
patients also exhibited 43% of hypocitraturia and 17% of 
hyperuricosuria while hypocitraturia and hyperuricos-
uria were present in 34 and 3% of normocalciuric pa-
tients, respectively. These disturbances appeared indi-
vidually or in association (data not shown in tables). As 
shown in  figure 1 , the  bb  genotype was overrepresented 
in the hypercalciuric group compared to the normocal-
ciuric group (43 vs. 27%, p  ! 0.05). The distribution of 
VDR genotypes in osteopenic or normal BMD patients 
was not statistically different, as illustrated in  figure 2 . 
 Table 2 shows serum and urinary parameters in these 
subgroups of normo- and hypercalciuric patients
grouped by VDR genotypes. Gender distribution, mean 
age, weight and serum parameters were not statistically 
different between the normo- and hypercalciuric groups 
with the same genotype or among genotypes, but the 
number of hypercalciuric patients presenting with the  bb 
 genotype was significantly higher.  Bb and  bb hypercal-
ciuric patients presented significantly higher mean uri-
nary uric acid excretion versus normocalciurics with the 
same genotype. Lower urinary citrate excretion was ob-
served in  bb when compared with  Bb  or  BB hypercalciu-
ric patients, without reaching statistical significance. 
When we examined the VDR alleles in normo- and hy-
percalciuric patients regarding recurrence, as seen in  ta-
ble 3 , we did not observe any statistically significant dif-
ferences in genotype distribution in patients who exhib-
ited or not new stone formation.
 With respect to CaSR polymorphisms in the whole 
sample, the 986S, 990G, and 1011E variant alleles were 
detected in 5, 4 and 3% of the patients, respectively. Ho-
mozygote genotypes for these variants were not found and 
the allele distribution conformed to the Hardy-Weinberg 
equilibrium for each CaSR polymorphism. No linkage 
disequilibrium was observed among the 3 single nucleo-
tide polymorphisms (data not shown). Five CaSR haplo-
types were identified in the present series, named accord-
ing to the amino acid coded at the 3 studied polymorphic 
sites. Their frequencies were: 94% ARQ (wild type), 3% 
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Table 2. Serum and urine biochemistry in subgroups of normocalciuric and hypercalciuric patients (means 8 
SD except for gender and age)
Genotype Normocalciuric (n = 101) Hypercalciuric (n = 100)
BB Bb bb BB Bb bb
Patients 14 60 27 18 39 43*
Gender, M/F 9/5 31/29 14/13 10/8 20/19 23/20
Age, years 41811 38811 45812 44811 3689 39813
Weight, kg 70810 64812 71810 69811 69812 69816
sCa, mg/dl 9.480.7 9.580.8 9.680.4 9.480.5 9.480.6 9.380.5
sCr, mg/dl 0.980.2 0.980.2 0.980.2 0.980.2 0.980.2 0.880.1
sUrAc, mg/dl 5.081.6 5.082.0 5.482.0 4.881.5 5.381.5 4.681.6
uCa, mg/24 h 162839 162838 145855 346883* 337861* 326860*
uNa, mEq/24 h 2118114 180869 219868 249899 226878 219882
uUrAc, mg/24 h 5078177 4688183 4858122 6118225 7068316* 6868239*
uCit, mg/24 h 3628197 3678194 3568195 4998285 4078318 3368230
* p < 0.05 versus normocalciuric patients with the same genotype. Conversion factors for SI units are: serum 
calcium sCa 0.2495 (for mmol/l), serum creatinine sCr 88.4 and serum uric acid sUrAc 59.48 (for mol/l); uri-
nary calcium uCa 0.02495, urinary sodium uNa 1.0 and urinary uric acid uUrAc 5.948 (for mmol/day); urinary 
citrate 0.053 (for mmol/l).
Table 3. VDR allele distribution in normo- or hypercalciuric patients with or without stone disease recur-
rence
Normocalciuric Hypercalciuric 
BB Bb bb BB Bb bb
Non-recurrent stones, n 13 (20%) 36 (54%) 17 (26%) 11 (22%) 16 (33%) 22 (45%)
Recurrent stones, n 3 (10%) 20 (67%) 7 (23%) 6 (13%) 22 (50%) 16 (37%)
New stones, n 1.781.2 2.681.8 1.880.8 2.381.6 2.581.9 2.081.1
New stones/year, n 0.480.3 0.881.1 1.081.7 0.380.2 0.680.7 0.380.2
Table 4. Serum and urine biochemistry in all patients according to the CaSR haplotypes
ARQ SRQ AGQ ARE AGE
Number 177 (94%) 10 (3%) 8 (1.5%) 4 (1.0%) 2 (0.5%)
sCa, mg/dl 9.480.6a 9.580.5 9.580.3 9.680.6 9.480.7
sCr, mg/dl 0.980.2 0.780.2 1.080.1 0.980.3 0.880.1
sAcUr, mg/dl 5.181.6 2.981.4 6.182.0 5.981.4 5.180.8
uCa, mg/24 h 2398100 280886 2838112 287880 300824
uNa, mEq/24 h 201867 246862 214876 235870 129879
uAcUr, mg/24 h 5808244 5828144 6648199 7188369 7708114
uCit, mg/24 h 3818232 5248402 2898136 217866 3258329
a Mean 8 SD. Conversion factor for SI units are: serum calcium 0.2495 for mmol/l, serum creatinine 88.4 
and serum uric acid 59.48 for mol/l; urinary calcium 0.02495, urinary sodium 1.0 and urinary uric acid 5.948 
for mmol/day; urinary citrate 0.053 for mmol/l.
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SRQ, 1.5% AGQ, 1.0% ARE and 0.5% AGE, as shown in 
 table 4 . Serum and urine biochemical analyses for each 
CaSR haplotype group were not statistically different 
among them. Patients with polymorphic sites (SRQ, AGQ, 
ARE, AGE) had an increased risk of presenting hypercal-
ciuria when compared to the ARQ wild type (OR, 2.8; 95% 
CI, 1.0 to 7.5; p = 0.042). However, as shown in  figure 3 , 
the frequencies of each haplotype were not significantly 
different between the normo- and hypercalciuric groups.
 Discussion 
 There is strong evidence that heredity is an important 
contributor to the prevalence of nephrolithiasis  [7, 11, 52, 
53] . The hypercalciuric phenotype has been implicated in 
the familial aggregation of stone formation  [54] ; kindreds 
with hypercalciuria have been well characterized  [55, 56] , 
and family-based studies showed a heritability for uri-
nary calcium excretion to be more than 50%  [57, 58] . The 
direct effects of 1,25(OH) 2 D 3 on renal calcium reabsorp-
tion are complex and not well understood because of in-
teractions with parathyroid hormone and simultaneous 
effects on intestine and bone. Hyperresponsiveness of 
 genetic hypercalciuric stone-forming rats to 1,25(OH) 2 D 3 
is unique and affects the VDR-responsive gene in 
1,25(OH) 2 D 3 target tissues possibly contributing to hy-
percalciuria and stone formation  [33] . Given the potential 
susceptibility locus in the vicinity of the VDR gene  [10] 
for idiopathic stone formation and the influence of cal-
cium-sensing receptor in calcium excretion  [34] , both 
VDR and  CaSR genes have been considered as candidate 
genes for idiopathic hypercalciuria. In the present study, 
we aimed at evaluating the association of both  VDR and 
 CaSR polymorphisms with urinary calcium excretion in 
calcium-stone-forming patients.
 We found a higher prevalence of the  bb genotype 
among hypercalciuric compared to normocalciuric pa-
tients. Inasmuch as  bb genotype has been classically re-
lated to a better BMD  [12–15] , its prevalence was expect-
ed to be lower among hypercalciuric patients, who tradi-
tionally exhibit higher rates of low BMD  [59–61] . Anyway, 
our findings regarding overrepresentation of the  bb gen-
otype agree well with the reports of Rendina et al.  [24] 
and Relan et al.  [32] , who also observed that the presence 
of two copies of the  b  allele was more common in hyper-
calciuric patients. Interestingly, although a higher preva-
lence of both ( ApaI ) aa and ( BsmI )  bb genotypes in fast-
ing hypercalciuric subjects disclosed in the former study 
 [24] , such  bb patients also presented a significantly lower 
instead of a higher mean BMD. In the present series, VDR 
allele distribution did not differ between osteopenic or 
normal BMD patients. In a previous evaluation by our 
group  [16] , conducted exclusively in hypercalciuric cal-
cium-stone-forming patients, we also found that VDR 
polymorphism was not associated with loss of BMD. Nor 
did Vezzoli et al.  [22] find an association of  FokI poly-
morphism with BMD in hypercalciuric patients. On the 
other hand, although several studies in the past have sug-
gested that multiple VDR polymorphisms (including 
 BsmI ) influence the regulation of BMD  [12–15] , a more 
recent multicenter prospective trial  [17] involving around 
26,000 participants, as well as other studies  [18, 19] , have 
not confirmed such an association. Two additional stud-
ies reported an association between  bb genotype with low 
rather than higher BMD  [20, 62] .
 Such observations of an association of VDR polymor-
phisms with calcium excretion but not with BMD are in-
triguing. According to Dawson-Hughes et al.  [63]  BB ho-
mozygous postmenopausal women, when exposed to low 
calcium intake, present less efficient intestinal calcium 
absorption than  bb women, despite similar levels of 
1,25(OH) 2 D 3 , pointing to VDR as functionally different 
between  BB  and  bb alleles. In agreement with our find-
ings, these investigators also observed that the  bb group 
exhibited somewhat higher levels (albeit not significant) 
of calcium excretion than  BB , coupled with similar BMD, 
irrespective of dietary calcium intake. Although the al-
tered gut VDR status in  bb variants might have been re-
sponsible for a better ability to increase fractional calci-
um absorption  [63] , the patients exhibited not only slight-
ly higher levels of urinary calcium but also somewhat 
lower serum PTH. The increase in calcium excretion in 
 bb genotypes may thus be ascribed to PTH suppression 
induced by increased activity of vitamin D. It is notewor-
thy that most studies which found a positive association 
of  bb alleles with BMD, had been performed in non-cal-
cium-stone-forming women  [12–15] whereas no associa-
tion was found in healthy males  [19] . Since males and 
females were equally distributed in the present study, the 
samples are not comparable. We also observed that the  bb 
homozygous patients exhibited a slightly higher mean 
urinary calcium excretion (although not significant) than 
heterozygous  Bb , in accordance with other investigators 
who reported the same results in stone formers  [21, 32] or 
non-stone formers  [64] . We believe that the small differ-
ences in mean urinary calcium excretion per genotype 
group might not have reached statistical significance be-
cause of the limited sample size presently analyzed. In 
hypercalciuric lithiasic children, Seyhan et al.  [29] found 
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a higher frequency of  tt genotypes. Conversely, other 
studies did not find any association between calcium ex-
cretion in nephrolithiasis patients with either  BsmI poly-
morphism  [20, 26, 65] or other polymorphisms as  TaqI , 
 ApaI or  FokI  [22, 26–30, 66] . In some reports in which 
hypercalciuria had been ascribed to intestinal calcium 
hyperabsorption or renal leak, no association between 
 BsmI polymorphism with absorptive hypercalciuria was 
found  [20, 25] while overrepresentation of  bb was ob-
served among those exhibiting renal leak  [24] . Since we 
found no differences of VDR alleles between absorptive 
or fasting hypercalciuric patients in a prior study encom-
passing a smaller number of patients  [16] , data regarding 
urinary calcium were pooled in the present analysis for 
comparison between normo- and hypercalciuric pa-
tients.
 In our sample, hypercalciuric patients with one or two 
copies of the  b allele also presented a statistically higher 
mean urinary uric acid excretion compared to normocal-
ciuric subgroups and a nonsignificant trend for lower uri-
nary citrate excretion when compared to hypercalciuric 
 BB patients. In another study in stone formers,  bb and  TT 
genotypes were found to be associated with the presence 
of hypocitraturia  [23] . However, the reasons why VDR 
polymorphisms might have affected the urinary excre-
tion of uric acid or citrate remain unclear. Finally, we did 
not find any association between  BsmI  alleles and stone 
recurrence in the normocalciuric or hypercalciuric 
groups. None of the studies that focused on the associa-
tion of VDR polymorphism with recurrence of stone dis-
ease had employed  Bsm I endonuclease. With regard to 
other polymorphisms, some authors have an association 
with recurrence or severity of stone disease with either 
the  t  allele  [27, 29] or the  FF genotype  [28] , while still 
other investigators observed nonsignificant trends for 
the  TT genotype  [30] .
 Taken together, conflicting results in the literature 
may be due, at least in part, to small sample sizes, differ-
ences in the studied populations (pre- and postmeno-
pausal women or kidney stone formers), sex, age, and ex-
act VDR polymorphism that had been investigated.
 With respect to CaSR polymorphisms, association 
with serum calcium have been reported in some studies 
 [12, 36, 67, 68] but not in all of them  [39, 47, 48, 69] . Few 
studies focused on the association of CaSR with urinary 
calcium in calcium-stone-forming patients  [38, 42] . In 
the present study, the frequencies of all 3 CaSR polymor-
phisms in the whole sample were very low (up to 5%). 
Although the presence of any variant allele conferred a 
2.8-fold increased risk of presenting hypercalciuria, we 
did not find any statistical differences among the vari-
ous haplotype distributions in normocalciuric versus 
hypercalciuric patients. These findings are in contrast 
with the data of Vezzoli et al.  [38] who observed that 
R990G polymorphism was associated with increased 
urinary calcium in calcium-stone-forming patients. A 
subsequent functional study performed by the same 
group  [40] with transfected cells containing the 990G 
variant showed a gain-of-function of the CaSR. A 5.5-
fold increased risk for the  G allele to develop hypercal-
ciuria was disclosed, but the study had not been per-
formed in stone formers, but in osteoporotic women in-
stead  [40] . It is also possible to infer that in such a setting, 
hypercalciuria was consequent to increased bone re-
sorption  [70] rather than being a primary mechanism 
leading to loss of bone mass. On the other hand, in an-
other functional study, Harding et al.  [43] did not find 
any change in CaSR activity in cells transfected for the 
990G allele. These investigators also reported a lack of 
association between R990G or other CaSR polymor-
phisms with urinary calcium in twin pairs  [43] . In an-
other Italian cohort, Scillitani et al.  [41] reported an 
overrepresentation of the AGQ haplotype in stone-form-
ing patients with primary hyperparathyroidism. Al-
though an association with calcium clearance was dis-
closed in that study, the urinary calcium values had been 
obtained from urine spot samples rather than from 24-
hour urine samples, which represent the gold-standard 
method. One limitation of this and other studies involv-
ing the R990G polymorphism and the Q1011E is the rel-
ative rarity of the 990G variant. We have currently found 
no homozygous patients for any of the 3 polymorphisms. 
Nevertheless, except for recent data by Cole et al.  [36] , 
who found 2.9% of stone formers to be homozygous for 
990G polymorphism, another study reported 1 single 
case in the control group or rates up to 1.6% of homozy-
gous  G among hypercalciuric patients  [40] , so that the 
results have mostly considered the heterozygous patients 
for statistical purposes.
 Although the present sample is not large and the sta-
tistic power of the present analysis is thus not optimal, 
some important points must be raised. First, genotype 
frequencies of either VDR or CaSR polymorphic sites did 
not deviate from the expected Hardy-Weinberg equilib-
rium in the current series. In addition, previous positive 
studies focusing on the association between calcium ex-
cretion and  BsmI  VDR polymorphisms among adult 
stone formers have involved around 150 patients  [24, 32] , 
an only moderately higher number than ours, while the 
negative studies included a much lower number of pa-
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